KRAS and pancreatic neoplasm: It should be highlighted that analysis of the mutational profile revealed that KRAS oncogene is mutated in approximately 93% of samples, with a subset of pancreatic tumors showing multiple variants in this gene, in addition to evidence of biallelic mutations [16].